Perspective Therapeutics Inc.
CATX | AMEX
$2.90
-$0.07 (-2.36%)
Sep 22, 2026, 2:03 PM ET · Market open
Market Data
Market Cap $338.72M
Enterprise Value $104.21M
Beta 1.80
Average Volume 1.54M
Shares Outstanding (Diluted) 120.65K
Shares Change YoY -99.83%
Institutional Ownership N/A
Exchange AMEX
ISIN US46489V3024
Price Performance
Price Change 1M -10.5%
Price Change 3M -1.0%
Price Change 6M -34.3%
Price Change YTD 6.5%
Price Change 1Y -10.0%
Price Change 3Y -0.7%
Price Change 5Y -55.0%
1M CAGR (ann.) -1.0%
1Y CAGR (ann.) -9.7%
5Y CAGR (ann.) -15.7%
All-Time CAGR -12.7%
Valuation
PE Ratio -2.08
Forward PE N/A
PEG Ratio 0.11
Forward PEG -0.36
PS Ratio 828.16
Forward PS 982.20
PB Ratio 1.05
P/FCF Ratio -2.79
P/Adj. FCF Ratio -2.58
P/OCF Ratio -2.36
EV/Sales 254.78
EV/EBIT -0.87
EV/EBITDA -0.90
EV/FCF -0.86
Earnings Yield -48.1%
FCF Yield -35.8%
Adj. FCF Yield -38.8%
Financial Health
Net Cash $234.51M
Total Debt $2.37M
Cash & Short-Term Investments $236.88M
Total Assets $392.03M
Current Ratio 6.61
Quick Ratio 6.61
Debt / Equity Ratio 0.01
Debt / EBITDA -0.02
Debt / FCF -0.02
OCF / Debt -39.34
Interest Coverage -410.60
Altman Z-Score 1.22
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin -419.4%
Operating Profit Margin -30619.1%
EBITDA Margin -31750.8%
Net Profit Margin -31812.6%
FCF Margin -29630.1%
Adj. FCF Margin -32090.7%
SBC / Revenue 2749.7%
SBC Impact (per share) -8.3%
Returns
Return on Assets -29.7%
Return on Equity -41.6%
Return on Invested Capital -34.9%
Return on Capital Employed -35.2%
Return on Tangible Assets -33.1%
Historical Growth (CAGR)
Revenue CAGR 3Y -61.0%
Revenue CAGR 5Y -47.3%
Revenue CAGR 10Y -21.8%
EPS CAGR 3Y -14.1%
EPS CAGR 5Y -42.2%
EPS CAGR 10Y -33.8%
FCF CAGR 3Y -55.6%
FCF CAGR 5Y -54.4%
FCF CAGR 10Y -37.4%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 12
EPS Growth Next 3Y 17.5%
Revenue Growth Next 3Y 458.7%
Earnings Date Nov 8, 2026
EPS Estimate (next Q) -$0.24
EPS Growth Est (next Q) -31.4%
Revenue Est (next Q) $62.15K
Revenue Growth Est (next Q) -70.3%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $11
Price Target Upside 270.4%
Cash Flow
Operating Cash Flow $-93.07M
Free Cash Flow $-121.19M
Adj. Free Cash Flow $-131.25M
FCF Per Share -$1.64
OCF Per Share -$1.26
OCF/S Ratio -25428.1%
Income Statement
Revenue $409K
Gross Profit $-2.5M
Operating Income $-125.23M
EBITDA $-116.21M
Net Income $-116.43M
EPS (Diluted) -$1.43
Revenue / Employee $2.48K
Profit / Employee $-705.66K
Employees 165
Add to Watchlist
Select watchlists to add or remove CATX